In our study, gefitinib-sensitive NSCLC cells, HCC827 cells, exhibited a gefitinib concentration-dependent decrease in cell viability and had deletional mutations (E746-A750) in EGFR exon 19, as previously reported. This evidence concerns the gene EGFR and non-small cell lung carcinoma.